Planning Committee Members The following Planning Committee members have no relevant financial relationship(s) with ineligible companies to disclose. Mastering E/M Changes for 2021 • Antanya Chung-Gardiner, BSc • Melesia Tillman 2021 Access in Rheumatology Planning Committee • Marcus Snow, MD 2021 Fellow-in-Training Educational Session Planning Committee • Nadia Elias, MD • Tate Johnson, MD • Justin Levinson, MD, MBA • Jean Lin, MD, PhD • Megan Lockwood, MD • Tyler Reese, MD • Zahra Rehman, MD • Didem Saygin, MD • Rachel Wallwork, MD 2021 State-of-the-Art Clinical Symposium Planning Committee • Sobia Hassan, MD • Aman Kugasia, MD • Jeanie Lee, MD • Manjari Malkani, MD • Rebecca Manno, MD, MHS The following Planning Committee members have relevant financial relationship(s) with ineligible companies to disclose. 2021 Access in Rheumatology Planning Committee • Christopher Phillips, MD - Pfizer (Self): 5 2021 Fellow-in-Training Educational Session Planning Committee • Mary Mamut, DO - Bendcare (Self): 8 2021 State-of-the-Art Clinical Symposium Planning Committee • Rohit Aggarwal, MD, MS - AbbVie, Amgen, , Genzyme, , Novartis, Roche, Sandoz, UCB (Self): 1, 5, 2; AdMIRx, Inc. / Now Q-32 (Self): 5, 2; Alexion (Self): 5; Argenx (Self): 5; AstraZeneca (Self): 5; Boehringer Ingelheim (BI) (Self): 5; Bristol-Myers Squibb(BMS) (Self): 5, 2; Corbus (Self): 5; CSL Behring (Self): 1, 5; EMD Serono (Self): 5, 2; Genentech (Self): 2; Janssen (Self): 5; Kezar (Self): 5; Kyverna (Self): 5; Mallinckrodt (Self): 1, 2; Octapharma (Self): 1, 5; Orphazyme (Self): 1; Pfizer (Self): 5, 2; Scipher Medicine: 5 • Narender Annapureddy, MD, MS - Medpage (Self): 1, Expert Reviewers for the ACR Reading Room section of MedPage Today. • Lianne Gensler, MD - AbbVie (Self): 1, 5; Eli Lilly (Self): 5; Gilead: 5; GSK (Self): 5; Janssen (Self): 5; Novartis (Self): 5; Pfizer (Self): 5, 2; UCB: 5 Faculty The following Faculty members have no relevant financial relationship(s) with ineligible companies to disclose. 2021 Access in Rheumatology • Colin Edgerton, MD • Susan Maddux, PharmD • Dipika Patel-Boolani, MD • Angus Worthing, MD • Sean Fahey, MD • Douglas White, MD, PhD 2021 Fellow-in-Training Educational Session • Monica Curtis, MD, MPH • Nadia Habal, MD • Nikolay Nikolov, MD • Elizabeth Blair Solow, MD • Joshua Stolow, MD • Tamika Webb-Detiege, MD • Rachel Wolfe, MD 2021 State-of-the-Art Clinical Symposium • Howard Blumstein, MD - United Rheumatology (Self): 1 • Sarah Emond - AbbVie Alnylam Pharmaceuticals America’s Health Insurance Plans (AHIP) Anthem AstraZeneca Biogen Blue Shield of CA Boehringer Ingelheim CVS Caremark Envolve Pharmacy Solutions (Self): Organization receives funding for a Policy Leadership Forum program from a mixture of health insurers and life science companies, including those listed above, 9; Express Scripts Genentech GlaxoSmithKline Harvard Pilgrim Health Care Health Care Service Corporation (HCSC) Healthfirst Humana Kaiser Permanente LEO Pharma Mallinckrodt Pharmaceuticals (Self): Organization receives funding for a Policy Leadership Forum program from a mixture of health insurers and life science companies, including those listed above, 9; Merck & Co. National Pharmaceutical Council (NPC) Novartis Pfizer Premera Blue Cross Prime Therapeutics Regeneron Sanofi United Healthcare uniQure (Self): Organization receives funding for a Policy Leadership Forum program from a mixture of health insurers and life science companies, including those listed above, 9 • Madelaine Feldman, MD - BMS (Self): 1; Eli Lilly (Self): 1; Gilead (Self): 1; Merck (Self): 1; Pfizer (Self): 1; samsung (Self): 1 • Jay Salliotte, MBA - AbbVie/Abbott (Self): 8; Cardinal Health (Self): 1; Genentech (Self): 8; Janssen (Self): 8; UCB (Self): 5 • Zachary Wallace, MD, MSc - Bristol-Myers Squibb(BMS) (Self): 2; MedPace (Self): 5; Principia (Self): 2; Viela Bio (Self): 5 • Elizabeth Perkins, MD - AbbVie/Abbott (Self): 5; Janssen (Self): 1; Novartis (Self): 5; Pfizer (Self): 1 2021 Fellow-in-Training Educational Session Monique Hinchcliff, MD, MS - Boehringer Ingelheim (Self): 5 • Aileen Pangan, MD - AbbVie/Abbott (Self): 3, 9, own stocks 2021 State-of-the-Art Clinical Symposium • Cassandra Calabrese, DO - AbbVie/Abbott (Self): 5; Sanofi-Regeneron (Self): 5, 8 • Anisha Dua, MD, MPH - AbbVie/Abbott (Self): 1, 8; ChemoCentryx (Self): 5; Novartis (Self): 1 • Rula Hajj-Ali, MD - Projects In Knowledge (Self): 8; ROCKPOINTE INC (Self): 8; UpToDate (Self): 7 • Kristin Highland, MD - Actelion Pharmaceuticals (Self): 5, 2, 8; Bayer Healthcare (Self): 8; Boehringer Ingelheim (Self): 1, 5, 2, 8; Genentech (Self): 5, 2, 8; Gossamer bio (Self): 2; Reata Pharmaceuticals (Self): 2, 8; United Therapeutics (Self): 5, 2, 8; Viela Bio (Self): 2 • Marc Hochberg, MD, MPH - Bone Therapeutics (Self): 5; Bri Ori Biotech (Self): 1; Centrexion Therapeutics (Self): 5; Eli Lilly (Self): 1, 5; Elsevier (Self): 7; EMD Serono: 9, Principal Investigator, FORWARD Trial; Flexion Therapeutics (Self): 5; Novartis (Self): 1, 5; Noven Pharmaceuticals Inc. (Self): 5; Pfizer (Self): 1, 5; Samumed LLC (Self): 5, 9, Support for medical writing and publication; Theralogix LLC (Self): 1, 5; Wolters Kluwer (Self): 7 • Marc Judson, MD - Mallinckrodt (Self): 2; Star Therapeutics (Self): 5 • Brian Mandell, MD, PhD - horizon (Self): 5, safety monitoring board • Javid Moslehi, MD - AstraZeneca (Self): 5; Bristol-Myers Squibb(BMS) (Self): 5; Takeda (Self): 5 • Alexis Ogdie, MD - AbbVie, Amgen, BMS, Celgene, Corrona, Eli Lilly, Gilead, Janssen, Novartis, Pfizer, UCB (Self): 5; Amgen (Self): 2; Novartis, Pfizer (Self): 2 • David Rubin, MD - AbbVie (Self): 5; Abgenomics/Altrubio (Self): 5; Allergan, Inc. (Self): 5; Arena Pharmaceuticals (Self): 5; Bellatrix Pharmaceuticals (Self): 5; Boehringer Ingelheim, Ltd (Self): 5; Bristol-Myers Squibb (Self): 5; CDx Diagnostics (Self): 5; Celgene Corp/Syneos (Self): 5; Check-Cap (Self): 5; Dizal Pharmaceuticals (Self): 5; GalenPharma/Atlantica (Self): 5; Genentech/Roche (Self): 5; Gilead Sciences (Self): 5; Ichnos Sciences S.A. (formerly Glenmark Pharmaceuticals) (Self): 5; InDex Pharmaceuticals (Self): 5; Iterative Scopes (Self): 5; Janssen Pharmaceuticals (Self): 5; Lilly (Self): 5; Materia Prima (Self): 5; Narrow River Management (Self): 5; Pfizer (Self): 5; Prometheus Laboratories (Self): 5; Reistone (Self): 5; Takeda (Self): 5, 2; Techlab (Self): 5 • Saira Sheikh, MD - Pfizer (Self): 2 • John Stone, MD, MPH - Genentech/Roche (Self): 5, 2; Principia Biopharma (Self): 5, 2; Sanofi (Self): 5; Viela Bio (Self): 5, 2 • Victoria Werth, MD - AbbVie/Abbott (Self): 5; Akari (Self): 5; Amgen (Self): 5, 2; Argenx (Self): 5, 2; Astra Zeneca (Self): 5, 8; Beacon Bioscience (Self): 5; Biogen (Self): 5, 2; BMS (Self): 5, 7; Corbus Pharmaceuticals (Self): 2; Corcept (Self): 5; CSL Behring (Self): 5, 2; Cugene (Self): 5; Eli Lilly (Self): 5; EMD Serona (Self): 5; Genentech (Self): 5, 7; Gilead (Self): 5, 2; GlaxoSmithKlein(GSK) (Self): 5; Kyowa Kirin (Self): 5; Octapharma (Self): 5; Pfizer (Self): 5, 2; Principiia (Self): 5; Regeneron (Self): 5, 2, 8; Resolve (Self): 5; Viela (Self): 5, 2 *All of the relevant financial relationships listed for these individuals have been mitigated. .